Pacific Biosciences
PACB
PACB
257 hedge funds and large institutions have $2.93B invested in Pacific Biosciences in 2023 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 86 increasing their positions, 60 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more funds holding
Funds holding: 234 → 257 (+23)
3.1% more ownership
Funds ownership: 99.44% → 102.54% (+3.1%)
Holders
257
Holding in Top 10
4
Calls
$59.3M
Puts
$18.5M
Top Buyers
| 1 | +$48.8M | |
| 2 | +$44.1M | |
| 3 | +$40.6M | |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$27.2M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$26.7M |
Top Sellers
| 1 | -$33.7M | |
| 2 | -$21.8M | |
| 3 | -$9.03M | |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$7.53M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$6.15M |